Knowledge, expectations and fears of cannabis use of epilepsy patients at a tertiary epilepsy center.


Journal

Epilepsy & behavior : E&B
ISSN: 1525-5069
Titre abrégé: Epilepsy Behav
Pays: United States
ID NLM: 100892858

Informations de publication

Date de publication:
10 2019
Historique:
received: 04 06 2019
revised: 17 07 2019
accepted: 26 07 2019
pubmed: 17 8 2019
medline: 21 7 2020
entrez: 17 8 2019
Statut: ppublish

Résumé

Medical cannabis is increasingly discussed as an alternative treatment option in neurological diseases, e.g. epilepsy. Supporters and opponents base their propositions mostly on subjective estimates, they confuse cannabis in whole versus extracts and botanical versus synthesized. Two hundred seventy five patients with any kind of epilepsy (56% female, 44% seizure free, 91% on medication) answered a survey on the knowledge, expectations, fears, and willingness to be treated with medical cannabis. Data were analyzed with regard to patient characteristics and clinical data from patient files. Overall, 70.5% of the patients were familiar with the possibility of medical cannabis treatment, 36.7% with its use in epilepsy. A minority of 10.9% gained the information from their physicians. The majority knew about organic compared to synthetic cannabis. The interest in further information is high (71.3%). Regression analysis (explaining 53.8% of the variance) indicated that positive expectations (in the order of relevance) were seizure control, relaxation, mood, and tolerability whereas fears mostly concerned addiction and delirant intoxication. Men showed a greater interest than women. Many epilepsy patients knew about medical cannabis, were interested in this treatment, and wanted more information. Expectations, however, appear to be based on the connotations of the whole substance cannabis with tetrahydrocannabidiol and its commonly known effects. Unfortunately, patients did not get their information from physicians, but mostly by other sources. In order to avoid prejudices and potentially harmful self-medication, physicians and healthcare providers are called to become familiar with the substance and to inform patients adequately.

Identifiants

pubmed: 31419634
pii: S1525-5050(19)30538-4
doi: 10.1016/j.yebeh.2019.106458
pii:
doi:

Substances chimiques

Anticonvulsants 0
Medical Marijuana 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106458

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Randi von Wrede (R)

University Hospital Bonn (UKB), Department of Epileptology, Germany. Electronic address: randi.von.wrede@ukbonn.de.

Susanna Moskau-Hartmann (S)

University Hospital Bonn (UKB), Department of Epileptology, Germany.

Nicola Amarell (N)

University Hospital Bonn (UKB), Department of Epileptology, Germany.

Christian Erich Elger (CE)

University Hospital Bonn (UKB), Department of Epileptology, Germany.

Christoph Helmstaedter (C)

University Hospital Bonn (UKB), Department of Epileptology, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH